Belantamab mafodotin 2.5 mg/kg (6 weeks) ( DrugBank: Belantamab mafodotin )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス1

28. 全身性アミロイドーシス


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05145816
(ClinicalTrials.gov)
August 1, 202323/11/2021Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisA Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisAL Amyloidosis;AmyloidosisDrug: Belantamab mafodotin 2.5 mg/kg (6 weeks);Drug: Belantamab mafodotin 2.5 mg/kg (4 weeks);Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks);Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks);Drug: Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosagesUniversity of Texas Southwestern Medical CenterGlaxoSmithKlineNot yet recruiting18 YearsN/AAll37Phase 1/Phase 2United States